CLDN18 Protein: Target Overview, Research Applications, and Selection Guide
15 products
15 products
Claudin 18 (CLDN18) is a member of the claudin family of tight junction proteins, which are essential components of epithelial barrier structures. CLDN18 exists in two main isoforms, CLDN18.1 and CLDN18.2, generated through alternative splicing. Among these, CLDN18.2 has emerged as a clinically relevant tumor-associated antigen, particularly in gastric and pancreatic cancers. Under normal physiological conditions, CLDN18.2 is largely confined to gastric mucosa and is buried within tight junctions, limiting antibody accessibility. However, in malignant transformation, tight junction disruption exposes CLDN18.2 on the cell surface, making it an attractive and highly specific therapeutic target.
CLDN18 is a four-pass transmembrane protein localized at tight junctions, functioning primarily in epithelial barrier maintenance. It plays roles in:
A key feature of CLDN18.2 is its tumor-restricted accessibility, which distinguishes it from many broadly expressed membrane targets. While not a signaling receptor or enzyme, CLDN18.2 serves as a structural and targeting antigen, enabling selective antibody-based therapies.
Target Name: CLDN18
Synonyms: Claudin-18; Claudin-18.2
UniProt ID: P56856
Target Class: Tight junction protein; transmembrane protein; tumor-associated antigen
CLDN18.2 becomes exposed on tumor cells due to tight junction disruption and can be specifically targeted by therapeutic antibodies. Antibody binding activates immune effector mechanisms such as ADCC and CDC, leading to tumor cell lysis.

CLDN18 is primarily used in oncology and antibody development workflows, especially for CLDN18.2-targeted therapies.
As a membrane structural protein, CLDN18 is best suited for cell-based and antibody-mediated assays, rather than biochemical enzyme workflows.
Submit an inquiry or email inquiry@betalifesci.com for a customization request or bulk order quote.
Fast turnaround production is available at a affordable price point if none of our catalog products fits your desire specifications.
Selection depends on isoform specificity (CLDN18.2), membrane context, and protein conformation. Proper selection ensures accurate representation of native antigen structure and reliable experimental outcomes.
If your project involves CLDN18.2 antibody discovery, tumor target validation, ADCC/CDC assays, or cell-based immunotherapy workflows, selecting the right CLDN18 format is essential for reliable results.
We can help you:
Submit your project details for expert evaluation. Our technical team will review your application and recommend the most suitable CLDN18 protein format for your research.
Qualified projects may be eligible for discounted or free samples for validation.
Subscribe today for the latest news and special offers.